Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
AHA News: Could the Pandemic Help Boost Diversity in Clinical Trials?Americans Still Avoiding ERs in Pandemic, But Uptick Seen in Mental Health CrisesCDC Panel Says It Needs More Time to Study J&J Vaccine Clotting CasesAHA News: 5 Things to Know This Earth Day About How the Environment Affects Health4 in 10 Adults Over 50 Consult Online Reviews When Picking a DoctorCBD or THC? Cannabis Product Labels Often Mislead, Study FindsPandemic Has Put Many Clinical Trials on HoldDespite Pandemic's Toll, Many Older Adults Don't Have Living Wills'Heart-in-a-Box' Can Be Lifesaving, Matching Up Distant Donors With PatientsPublic Lost Trust in CDC During COVID Crisis: PollNearly 8 in 10 School, Child Care Staff Have Gotten at Least 1 Dose of COVID Vaccine: CDCWhy Are ER Wait Times Getting Longer for Kids in Mental Health Crisis?Buying Your Own Health Insurance Just Got Way Less ExpensiveStrain of COVID Care Has Many Health Professionals Looking for an ExitBlack Americans Often Face Discrimination in Health CareHow Willing Are Americans to Donate COVID Vaccines to Other Countries?Too Few Minorities in U.S. Health Care Workforce: ReportBlack Patients Often Treated at Hospitals With Poorer Safety Records: ReportDon't Delay Your Cancer Screenings, Surgeons' Group UrgesBiden Administration Working on 'Vaccine Passport' InitiativeStates Race to Vaccinate Their ResidentsFDA Clamping Down on Abuse of an OTC  DecongestantShortage of Primary Care Doctors Is Costing American LivesStudy Finds Growing Acceptance of COVID Vaccine by U.S. Health Care Workers'Avoidable Hospitalizations:' Another Way the Pandemic Is Tougher on MinoritiesOn-the-Road Help: 'Mobile Stroke Units' Are Saving People's LivesTalks With Doctors May Be Key to Vaccine Acceptance: StudyAs U.S. Vaccinations Rise, Are 'Vaccine Passports' for Americans Coming?Begin Routine Diabetes Screening at 35 for Overweight, Obese Americans: Task Force'Race Gap' in U.S. Heart Health Has Changed Little in 20 Years: ReportDriven by Anti-Vaxxers, Measles Outbreaks Cost Everyone MoneyScams Await Many Americans Desperate to Get COVID VaccineMore Americans Would Get Lung Cancer Screening Under New GuidelinesGlobal Warming Could Make Survival in Tropics Impossible: StudyCDC Issues New Guidelines for Vaccinated AmericansAHA News: How Science Evolved Its Views on Women's HealthHow Moving the Homeless to Hotels During the Pandemic Helps EveryoneFormaldehyde in Hair Straighteners Prompts FDA WarningPandemic Is Hitting Hospitals Hard, Including Their Bottom LineGot a Vaccine-Skeptical Relative? Here's How to Talk to Them1 in 3 Americans Delayed, Skipped Medical Care During PandemicHealth Care After COVID: A New Focus on Infectious DiseasesMost Americans Unhappy With U.S. Vaccine Rollout: PollBedside Manner Even More Important for Hospital Patients Admitted Via the ERToo Many U.S. Doctors Biased Against Patients With Disabilities: StudyWhy Do Black Children Get Fewer Scans When They're Seen in ERs?Compared to Other Countries, Americans Pay Much More for Prescription DrugsAnti-Vaxxers Mounting Internet Campaigns Against COVID-19 ShotsPandemic Has Greatly Slowed Pace of Cancer ResearchCrowdsourcing Raises Billions for Families Hit Hard by Medical Bills
Links
Related Topics

Health Insurance
Healthcare

Pandemic Has Greatly Slowed Pace of Cancer Research

HealthDay News
by By Alan Mozes HealthDay Reporter
Updated: Jan 27th 2021

new article illustration


WEDNESDAY, Jan. 27, 2021 (HealthDay News) -- To the ever-growing list of COVID-19's collateral damage, add one more casualty: cancer research.

A new study indicates that during the first wave of the pandemic last spring, the number of newly launched cancer treatment studies cratered by 60%.

"In short, the first wave of COVID slowed scientific progress in a health-related area distant from the disease itself," said study author Dr. Elizabeth Lamont, senior medical director of Acorn AI, in Boston.

The finding follows a review of data collected by the Medidata Enterprise Data Store, which accounts for nearly 30% of all cancer research. The team tallied all new cancer studies launched between January and May of 2020, when the pandemic began. These were then compared with numbers stretching back during comparable time periods over the four prior years.

The upshot: 1,249 studies were launched pre-pandemic, averaging out to 312 studies per year. That compared with just 191 studies since the pandemic began, the researchers reported.

The good news is that, more recently, "our ongoing surveillance and research suggests that there has been a rebound in [cancer] trial launches," Lamont said.

Still, the findings, published online Jan. 27 in JAMA Network Open, "only tell part of the disturbing story," warned Dr. Richard Schilsky, chief medical officer of the American Society of Clinical Oncology (ASCO).

"This study speaks to a big decline in the launch of new trials during the pandemic," Schilsky noted. "But that doesn't say anything about the number of cancer trials that were suspended, put on hold, or in which enrollment rates drastically plummeted. In fact, the number of ongoing trials fell on the order of 50% last spring."

Why? Lamont said her study "was not designed to ascertain the reasons for the downward trend in oncology trial launches."

But Schilsky pointed to "a variety of factors" that might be at play.

"Certainly, social distancing is part of it," he noted. "Especially when you're talking about vulnerable cancer patients. Many patients were fearful. Understandably. Study treatments are unproven, and many patients didn't want to risk exposure to COVID in order to get an unproven treatment."

But in large part the problem was a matter of staffing, Schilsky said.

"When the pandemic hit full force in March and April, scientists had not yet been able to adapt their processes to operate safely. So many research staff were simply sent home, for their own protection. And some scientists -- the ones who were clinically trained -- were then pulled to help meet the clinical [COVID-19-related] needs of their various institutions. So, of course, all of that seriously undermined the ability of research sites to adequately staff their studies," Schilsky explained.

The other issue was that much of the non-COVID-related health care industry went into shutdown.

"Many processes are needed to support clinical trials," Schilsky said. "For example, biopsies in an interventional radiology suite. But a lot of that was put on hold. Also, a lot of times research studies are considered to be 'elective procedures,' and they were the first to go."

But he agreed with Lamont that the cancer research scene has managed a partial rebound, despite the ongoing pandemic.

"Research and development is adapting to the substantial challenges that COVID-19 continues to pose, which is cause for great optimism," Lamont said. Engaging patients via telemedicine, when possible, was one big shift. And she hailed adaptive regulatory support for helping to facilitate such changes.

Adaptation was the name of the game, Schilsky agreed.

"The U.S. Centers for Disease Control and Prevention, for example, changed their procedures so as to be able to operate more safely, allowing research staff to complete their responsibilities working from home, as long as they had access to medical records and electronic data capture systems that they need. And trial sponsors also began to modify their trial requirements," he said.

Yet there's no question that the pandemic will have taken a big toll, Schilsky cautioned. "Some trials never resumed and may never. Some sponsors may abandon them. Most will resume, if they haven't already, but they lost months of enrollment time. And that's going to delay results. And at the end of the day, this means there will be long-term implications with respect to how quickly new cancer treatments can come to market," he said.

More information

There's more on cancer research during the pandemic at ASCO.

SOURCES: Elizabeth Lamont, MD, senior medical director, Acorn AI, Boston; Richard Schilsky, MD, chief medical officer, American Society of Clinical Oncology (ASCO), Alexandria, Va.; JAMA Network Open, Jan. 27, 2021, online




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net